In a fitting move for Tandem Diabetes Care, the San Diego-based company is joining forces with another maker of insulin pumps to instantly double its diabetes technology offerings.

Meet the most important molecules you’ve (probably) never thought about: adhesion molecules, proteins on the surface of cells that help them communicate and coordinate with each other. They’re vital to a myriad of processes, from tissue formation to neuronal connections and immune cell signaling.

Merck & Co. has shown why it bet $250 million on Moderna’s mRNA cancer immunotherapy. Weeks after Merck opted into the program, the partners have revealed the personalized candidate reduced the risk of recurrence or death by 44% when given to melanoma patients in combination with Keytruda.

Regeneron is boasting about having the highest complete response rate for advanced follicular lymphoma, but a question hangs heavy over the most recent data: Can the bispecific overcome a slate of deaths and serious adverse events that have occurred in several trials?

On the heels of its FDA submission, Johnson & Johnson is unveiling results used to woo regulators on its bispecific antibody in multiple myeloma patients in dire need of successful treatment.

In its second safety alert this year, Smiths Medical has issued a letter to its customers detailing a pair of potential issues with the infusion sets used alongside its CADD line of infusion systems.

Roche’s attempt to muscle in on paroxysmal nocturnal hemoglobinuria (PNH) is on track. The subcutaneous anti-C5 recycling antibody crovalimab improved outcomes in a Chinese phase 3 trial, giving the Big Pharma a boost as it closes in on data from its showdown with AstraZeneca’s Soliris.

Two years ago, clouds gathered over Regeneron’s blood cancer candidate odronextamab after it reported five treatment-related deaths and the FDA placed a clinical hold on studies. Now, the company is back with the data it hopes will secure approval—and has again reported five deaths linked to the therapy.

Five years after Legend Biotech made a splash with an initial 100% tumor response rate for what would later become Johnson & Johnson-partnered Carvykti, another Chinese company has repeated the same remarkable data for its BCMA-targeted CAR-T therapy, this time in an earlier multiple myeloma setting.

Cytokinetics will finally get the chance to make the case for its heart failure drug to the FDA’s advisory committee next week. But it seems the agency is uneasy about the single study used to support the application and whether that phase 3 test covered some of the company’s asks.